公开(公告)号：KR1020150022731A

公开(公告)日：2015-03-04

申请号：KR1020140110919

申请日：2014-08-25

Applicant: 가톨릭대학교 산학협력단

Inventor： 조미라 ,  양철우 ,  신동윤 ,  박민정 ,  이선영 ,  이성희 ,  양은지 ,  손혜진 ,  김은경 ,  김재경

IPC: A61K31/155 ,  A61K31/36 ,  A61P29/00

CPC classification number: A61K31/155 ,  A61K2121/00 ,  A61K2300/00 ,  C07C279/18 ,  C07C279/26

Abstract: 본 발명은 면역질환을 효과적으로 예방 및 치료할 수 있는 바이구아나이드(biguanide) 유도체 화합물에 관한 것이다. 본 발명의 바이구아나이드계 유도체 화합물은 염증성 사이토카인인 IL-17 및 TNF-α의 생성을 억제시키며, 면역조절 기능을 갖는 조절 T 세포의 활성을 증대시킬 뿐만 아니라, 면역질환 동물모델에 대해 우수한 치료 효과를 나타낸다. 따라서 각종 면역반응의 조절 이상으로 유발되는 자가면역질환, 염증성질환 및 이식거부질환과 같은 면역질환을 예방 또는 치료할 수 있는 약학적 조성물 또는 면역 억제제로 유용하게 사용될 수 있다.

Abstract translation: 本发明涉及能够有效预防和治疗免疫疾病的双胍衍生物。 本发明的双胍衍生化合物抑制作为炎症细胞因子的IL-17和TNF-α的产生，增加具有免疫调节功能的调节性T细胞的活性，并且在具有免疫疾病的动物模型中表现出优异的治疗效果 。 因此，双胍类衍生化合物可以有利地用作免疫抑制剂或能够预防或治疗由免疫应答失调引起的各种免疫疾病如自身免疫性疾病，炎性疾病和移植排斥的药物组合物。

公开(公告)号：KR1020140038898A

公开(公告)日：2014-03-31

申请号：KR1020130111679

申请日：2013-09-17

Applicant: 가톨릭대학교 산학협력단

Inventor： 조미라 ,  이선영 ,  양은지 ,  손혜진 ,  김은경 ,  유준걸

IPC: A61K31/155 ,  A61P29/00 ,  A61P1/00

CPC classification number: A61K31/155 ,  A61K38/1793 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to a composition for preventing or treating inflammatory bowel diseases comprising metformin as an active ingredient. A metformin compound or a composite of the metformin and etanercept (product name: Enbrel) have an excellent effect in maintaining the thickness of small intestines and the length of large intestines in a state similar to a normal state, an excellent effect in controlling or reducing the activity of IL-17 and TNF-a, and an excellent effect in promoting or increasing the activity of IFNr, thereby able to be practically used as a pharmaceutical composition for preventing or treating autoimmune diseases including the treatment of inflammatory bowel diseases.

Abstract translation: 本发明涉及一种预防或治疗包含二甲双胍作为活性成分的炎症性肠病的组合物。 二甲双胍化合物或二甲双胍和依那西普（产品名：Enbrel）的复合物在保持小肠厚度和大肠的长度处于类似于正常状态的状态下具有优异的效果，控制或减少的优异效果 IL-17和TNF-α的活性，并且在促进或增加IFNr的活性方面具有优异的效果，从而能够实际上用作预防或治疗包括治疗炎症性肠病的自身免疫性疾病的药物组合物。

公开(公告)号：KR1020140036598A

公开(公告)日：2014-03-26

申请号：KR1020120102887

申请日：2012-09-17

Applicant: 가톨릭대학교 산학협력단

Inventor： 조미라 ,  이선영 ,  박민정 ,  이재선 ,  양은지 ,  김은경 ,  유준걸 ,  손혜진

IPC: A61K31/155 ,  A61P37/00

CPC classification number: A61K31/155

Abstract: The present invention relates to a composition for preventing or treating immune diseases by suppressing B cell activities which are induced by metformin and, more specifically, to a composition for preventing or treating immune diseases, which includes a metformin compound or pharmaceutically acceptable salts thereof. The composition suppresses or reduces activities of etiological B cells. According to the present invention, the composition for preventing or treating immune diseases can be used as an immune suppressor by suppressing or reducing the etiological B cells in various autoimmune diseases, suppressing or reducing activities of etiological Th17 cells, and promoting or increasing activities of regulatory T cells (Treg).

Abstract translation: 本发明涉及通过抑制二甲双胍诱导的B细胞活性，更具体地说，涉及包含二甲双胍化合物或其药学上可接受的盐的免疫疾病的预防或治疗组合物，用于预防或治疗免疫疾病的组合物。 该组合物抑制或减少病原B细胞的活性。 根据本发明，用于预防或治疗免疫疾病的组合物可以通过抑制或减少各种自身免疫疾病中的病原B细胞，抑制或减少病原Th17细胞的活性，以及​​促进或增加调节活性 T细胞（Treg）。

公开(公告)号：KR1020140031614A

公开(公告)日：2014-03-13

申请号：KR1020120098140

申请日：2012-09-05

Applicant: 가톨릭대학교 산학협력단

Inventor： 조미라 ,  전주연 ,  이선영 ,  문영미 ,  유준걸 ,  변재경 ,  손혜진 ,  김은경 ,  양은지

IPC: A61K38/17 ,  G01N33/68 ,  C07K14/47

CPC classification number: A61K38/1709 ,  A61K38/1761 ,  C07K14/47 ,  G01N33/6872 ,  G01N33/6893 ,  G01N2333/4704 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2800/044

Abstract: The present invention relates to a composition for preventing or treating obesity or metabolic diseases which includes Grim19 protein as an active ingredient and, specifically, to a composition for preventing or treating obesity or metabolic diseases including Grim19 protein as an active ingredient which can prevent or treat metabolic diseases caused by immune response disorder or interactions of genetically, metabolically, and environmentally complex factors. The Grim 19 proteins according to the present invention, fat cell reduction effects and total in vivo cholesterol amount are enhanced, suppression of differentiation of cytotoxic Th17 cells which produce and secrete inflammatory cytokine is enhanced, and effects of controlling inflammatory environment related to obesity using STAT3 as a mediator by the Grim19 so that the Grim 19 proteins can be used for manufacturing medicines and functional foods which can effectively treat obesity or lipid related metabolic diseases.

Abstract translation: 本发明涉及用于预防或治疗肥胖或代谢疾病的组合物，其包括Grim19蛋白作为活性成分，具体地，涉及用于预防或治疗肥胖症或代谢疾病的组合物，包括Grim19蛋白作为活性成分，其可以预防或治疗 由免疫应答障碍引起的代谢疾病或遗传，代谢和环境复杂因素的相互作用。 根据本发明的Grim19蛋白质，脂肪细胞减少作用和总体内胆固醇含量增强，产生和分泌炎症细胞因子的细胞毒性Th17细胞分化的抑制被增强，并且使用STAT3来控制与肥胖有关的炎症环境的效果 作为Grim19的调解人，使Grim 19蛋白质可用于制造能够有效治疗肥胖或脂质相关代谢疾病的药物和功能性食品。